Medicinova (MNOV)

Medicinova (MNOV) Income Statement


Medicinova Income Statement

Last quarter (Q1 2023), Medicinova's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Medicinova's net income was $-2.92M. See Medicinova’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--$ 4.04M$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ 7.72M$ -14.63M$ 14.25M$ 14.18M$ 14.03M$ 15.59M
Operating Income
$ -14.18M$ -14.63M$ -10.22M$ -14.18M$ -14.03M$ -15.59M
Net Non Operating Interest Income Expense
$ 1.28M$ 809.67K$ 143.63K$ 361.18K$ 1.15M$ 939.91K
Other Income Expense
$ 619.23K$ 247.28K$ -59.50K$ -38.40K$ -46.16K$ -22.89K
Pretax Income
$ -13.60M$ -14.07M$ -10.13M$ -13.86M$ -12.93M$ -14.67M
Tax Provision
$ 2.82K$ 2.82K$ 2.57K$ -1.65K$ 12.66K$ 5.28K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -13.60M$ -14.07M$ -10.13M$ -13.85M$ -12.94M$ -14.68M
Basic EPS
$ -0.35$ -0.29$ -0.21$ -0.31$ -0.30$ -0.36
Diluted EPS
$ -0.28$ -0.29$ -0.21$ -0.31$ -0.30$ -0.36
Basic Average Shares
$ 196.18M$ 49.05M$ 48.60M$ 44.41M$ 43.16M$ 41.12M
Diluted Average Shares
$ 196.18M$ 49.05M$ 48.60M$ 44.41M$ 43.16M$ 41.12M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 7.72M$ -14.63M$ 14.25M$ 14.18M$ 14.03M$ 15.59M
Net Income From Continuing And Discontinued Operation
$ -13.60M$ -14.07M$ -10.13M$ -13.85M$ -12.94M$ -14.68M
Normalized Income
$ -7.68M-$ -10.13M$ -13.85M$ -12.94M$ -14.68M
Interest Expense
$ -14.84M$ -14.88M$ -10.22M$ -14.18M$ -14.03M$ -15.59M
$ -14.82M$ -14.86M$ -10.19M$ -14.16M$ -14.01M$ -15.56M
Currency in USD

Medicinova Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis